As a Novel Prognostic Marker, Cysteine/histidine-rich 1 (CYHR1) is a Therapeutic Target in Patients with Esophageal Squamous Cell Carcinoma

Ryosuke Desaki, Genta Sawada, Hiroshi Okumura, Ryuji Ikeda, Kan Tanabe, Hisateru Komatsu, Koshi Mimori, Masaki Mori, Yoshiaki Kita, Yasuto Uchikado, Takaaki Arigami, Yoshikazu Uenosono, Tetsuhiro Owaki, Sumiya Ishigami, Shoji Natsugoe

研究成果: Contribution to journalArticle査読

抄録

Background: Cysteine/histidine-rich 1 (CYHR1) was first discovered in a yeast two-hybrid screen with murine galectin-3, and no previous reports have described a relationship between the CYHR1 gene and human cancer. The current study evaluated the role and significance of CYHR1 in esophageal cancer. Methods: The human esophageal squamous cell carcinoma (ESCC) cell line TE-8 and the CYHR1 knock-down cell line TE-8/small interfering (si)-CYHR1 were used for in vitro and in vivo assays. For clinical study, ESCC tissues (n = 104) were used. Results: Compared with parental cells, TE-8/si-CYHR1 cells had suppressed proliferation and invasion activities. In the in vivo assay, the tumors from TE-8 cells treated with si-CYHR1 had abrogated tumorigenicity. In the clinical study, the expression of CYHR1 mRNA was associated with lymph node metastasis and stage and shown to be an independent prognostic factor. Conclusions: As the findings show, CYHR1 may represent not only a valuable prognostic marker but also a therapeutic target for ESCC patients.

本文言語英語
ページ(範囲)586-593
ページ数8
ジャーナルAnnals of Surgical Oncology
24
2
DOI
出版ステータス出版済み - 2 1 2017
外部発表はい

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

フィンガープリント 「As a Novel Prognostic Marker, Cysteine/histidine-rich 1 (CYHR1) is a Therapeutic Target in Patients with Esophageal Squamous Cell Carcinoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル